The Joslin Diabetes Center in Boston was established in 1898, more than 25 years before the discovery of insulin, and has been at the forefront of diabetes research, treatment, patient and professional education ever since. Joslin is affiliated with Harvard Medical School and has enjoyed a rich history of important discoveries and innovations. These include:
Pioneering the team model of diabetes care and involving the patient in understanding and managing his own disease-a concept established by founder Elliott P. Joslin, M.D. and his colleagues in the early years of this century; Emphasis on tight control of blood sugars as a means of preventing diabetes complications. This controversial focus of the Joslin-style of patient care endured ridicule in many quarters for over 60 years until the nationwide Diabetes Control and Complications Trial proved conclusively that tight blood sugar control reduces complications; Development of clinical protocols by Priscilla White, M.D., and those who followed her, that raised the fetal survival rate for diabetic women from only 50% at mid-century to over 96% today; Seminal work in the development of laser photocoagulation to treat diabetic eye disease; Identification of the means to tell who is most likely to develop type 1 diabetes years in advance of symptoms and the identification of treatment strategies now in nationwide NIH clinical trials, to see if this form of the disease can be prevented; Multiple discoveries related to the fundamental mechanisms of insulin action, islet cell regulation and mechanisms of tissue injury to vascular tissues in diabetes. The Joslin Clinic offers services including adult diabetes and endocrinology, pediatric diabetes and endocrinology, ophthalmology, mental health, diabetic pregnancy, and diabetes care. In 1999, the Clinic formed a joint venture with CareGroup and Beth Israel Deaconess Medical Center to further strengthen its ability to provide the complete range of diabetes services patients require. Joslin has also broadened its patient care and professional education activities beyond Boston in the past decade, establishing more than 20 Joslin Centers at selected sites around the United States and conducting an estimated 90 continuing medical education programs reaching more than 30,000 physicians, nurse practitioners and other diabetes care providers each year. Both the clinic and research activities are housed in a facility that takes up most of a city block in Boston's Longwood Medical Area of Harvard teaching hospitals.
Current Research and Clinical Programs

Research Strengths
One of the key features in the design of the Joslin Research Program has been to create an environment in which there is both breadth and depth. A breadth of topics is needed to cover the many areas of knowledge which are required for research into diabetes and its complications. A depth of expertise is found in most areas where there are several investigators with common interests and overlapping areas of expertise that maximize both individual and group productivity. In addition, because of the breadth of the research programs needed to deal with both type 1 (insulindependent) and type 2 (non-insulin depen- His special research interests include: insulin action and insulin resistance particularly as it relates to type 2 diabetes; the genetics of diabetes; and the pathophysiology of diabetes. Much of the work in the Section on Cellular and Molecular Physiology, which he heads, centers around understanding the mechanism of action of insulin and related hormones, how insulin action pathways are altered in diabetes and other disease states, and how insulin action can be mimicked or improved as an approach to the treatment of diabetes.
Since the initial discovery by his laboratory that the insulin receptor is an insulinstimulated enzyme with protein tyrosine kinase activity, the Kahn laboratory has focused its attention on how this early signal is converted to the final effects of insulin on metabolism and growth, how insulin signaling is altered in insulin-resistant states such as type 2 diabetes, and what the impact of genetics is on these functions. Following the activation of the receptor kinase, several intracellular substrates become tyrosine phosphorylated. The best studied of these are two related high molecular weight proteins, termed insulin receptor substrates 1 and 2 (IRS-1 and IRS-2). These phosphorylated proteins serve as docking sites for other intracellular signaling proteins (SH2 proteins) and link insulin stimulation to two major intracellular cascades: one is the pathway mediated by an intracellular enzyme phosphatidylinositol 3-kinase (PI 3-kinase) and the other is the Ras pathway. This forms an important point of diversion in insulin signaling and several potential points of regulation in disease.
Current projects in the laboratory include defining the roles of the IRS proteins and PI 3-kinase in the insulin-signaling pathway through the creation of new cell lines and animal models in which these proteins are either eliminated by a genetic "knock-out" or increased by overexpression. This has led to identification of previously unrecognized pathways of signaling and creation of the first polygenic model of type 2 diabetes in rodents which resembles human type 2. This lab also has used molecular genetic techniques to identify novel intermediates for the PI 3-kinase pathway and regulation of calcium flux by insulin in important target tissues, such as skeletal and cardial muscle.
Dr. Kahn also is characterizing the alterations in inslin-signaling at a molecular level in insulin-resistant states, especially type 2 diabetes (NIDDM), and determining how this signaling system interacts with other hormonal and metabolic signals. Both genetic and acquired alterations in multiple steps of these signaling pathways have been observed. The Kahn laboratory is studying ways to overcome this insulin-resistance and improve diabetes control in humans and in rodents. These researchers also have defined novel interactions between the insulin-signaling pathway and the action of vasoactive hormones, such as angiotensin II, which may contribute to the association between diabetes, hypertension and accelerated cardiovascular disease.
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